Last reviewed · How we verify

Remimazolam besylate + propofol MCT

Chung-Ang University Gwangmyeong Hospital · FDA-approved active Small molecule

Remimazolam besylate + propofol MCT is a Benzodiazepine + propofol combination sedative-hypnotic Small molecule drug developed by Chung-Ang University Gwangmyeong Hospital. It is currently FDA-approved for Procedural sedation and anesthesia.

Remimazolam besylate is a benzodiazepine that enhances GABAergic inhibition in the central nervous system, while propofol MCT is a lipophilic sedative-hypnotic that potentiates GABA receptor activity; together they provide rapid-onset, short-acting sedation and anesthesia.

Remimazolam besylate is a benzodiazepine that enhances GABAergic inhibition in the central nervous system, while propofol MCT is a lipophilic sedative-hypnotic that potentiates GABA receptor activity; together they provide rapid-onset, short-acting sedation and anesthesia. Used for Procedural sedation and anesthesia.

At a glance

Generic nameRemimazolam besylate + propofol MCT
SponsorChung-Ang University Gwangmyeong Hospital
Drug classBenzodiazepine + propofol combination sedative-hypnotic
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesia/Sedation
PhaseFDA-approved

Mechanism of action

Remimazolam is a rapid-onset, short-acting benzodiazepine agonist at GABA-A receptors that is metabolized by esterases, allowing quick reversal with flumazenil if needed. Propofol MCT (medium-chain triglyceride formulation) is an intravenous hypnotic that acts as a positive allosteric modulator of GABA-A receptors. The combination provides synergistic sedative and anesthetic effects for procedural sedation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Remimazolam besylate + propofol MCT

What is Remimazolam besylate + propofol MCT?

Remimazolam besylate + propofol MCT is a Benzodiazepine + propofol combination sedative-hypnotic drug developed by Chung-Ang University Gwangmyeong Hospital, indicated for Procedural sedation and anesthesia.

How does Remimazolam besylate + propofol MCT work?

Remimazolam besylate is a benzodiazepine that enhances GABAergic inhibition in the central nervous system, while propofol MCT is a lipophilic sedative-hypnotic that potentiates GABA receptor activity; together they provide rapid-onset, short-acting sedation and anesthesia.

What is Remimazolam besylate + propofol MCT used for?

Remimazolam besylate + propofol MCT is indicated for Procedural sedation and anesthesia.

Who makes Remimazolam besylate + propofol MCT?

Remimazolam besylate + propofol MCT is developed and marketed by Chung-Ang University Gwangmyeong Hospital (see full Chung-Ang University Gwangmyeong Hospital pipeline at /company/chung-ang-university-gwangmyeong-hospital).

What drug class is Remimazolam besylate + propofol MCT in?

Remimazolam besylate + propofol MCT belongs to the Benzodiazepine + propofol combination sedative-hypnotic class. See all Benzodiazepine + propofol combination sedative-hypnotic drugs at /class/benzodiazepine-propofol-combination-sedative-hypnotic.

What development phase is Remimazolam besylate + propofol MCT in?

Remimazolam besylate + propofol MCT is FDA-approved (marketed).

What are the side effects of Remimazolam besylate + propofol MCT?

Common side effects of Remimazolam besylate + propofol MCT include Respiratory depression, Hypotension, Bradycardia, Injection site pain.

What does Remimazolam besylate + propofol MCT target?

Remimazolam besylate + propofol MCT targets GABA-A receptor and is a Benzodiazepine + propofol combination sedative-hypnotic.

Related